Pricing

Albireo Pharma Inc (ALBO)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ronald H. W. Cooper
Employees:
130
10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109
857-415-4774
Stock Split History
DateRatio
2012-06-12 1:4
2016-11-04 1:30
Albireo Pharma, Inc. focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children. It also engages in the developing of A3907, A2342, a preclinical candidate to treat adult viral and liver diseases.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available